Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression
Anticancer Research · 2024
DOI: 10.21873/anticanres.17214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Shuhei Suzuki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan; s-suzuki@med.id.yamagata-u.ac.jp. Hauptthemen laut MEDLINE: Glioblastoma, Survivin, alpha-MSH. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan; s-suzuki@med.id.yamagata-u.ac.jp.
- Department of Clinical Oncology, Yamagata Prefectural Shinjo Hospital, Yamagata, Japan.
- Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan.
- Research Institute for Promotion of Medical Sciences, Yamagata University Faculty of Medicine, Yamagata, Japan.
Zitieren
APA
Suzuki, S., Kitanaka, C., & Okada, M. (2024). Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression. Anticancer Research. https://doi.org/10.21873/anticanres.17214
Vancouver
Suzuki S, Kitanaka C, Okada M. Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression. Anticancer Research. 2024. doi:10.21873/anticanres.17214
BibTeX
@article{Suzuki2024,
author = {Suzuki, Shuhei and Kitanaka, Chifumi and Okada, Masashi},
title = {Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17214}
}
EUVIMED